High rate of completion of preventive therapy for latent tuberculosis infection among asylum seekers in a Swiss Canton

Swiss Medical Weekly

Volumn 143, Issue , 2013, Pages

  Sarivalasis, Apostolos ^a   Bodenmann, Patrick ^a   Langenskiold, Elisabeth ^b   Lutchmaya Flick, Caroline ^c   Daher, Oscar ^c   Zellweger, Jean Pierre ^d  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Health Centre Sainte Croix Hospital (CSSC)   (Switzerland)

^d Swiss Lung Association   (Switzerland)

Author keywords

Asylum seekers; LTBI; Preventive treatment; Rifampicin; Tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; COHORT ANALYSIS; FOLLOW UP; HOUSING; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LUNG DISEASE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; MIGRATION; PATIENT REFERRAL; PROPHYLAXIS; PROSPECTIVE STUDY; SCREENING; TREATMENT CONTRAINDICATION; ADULT; AFRICA; ASIA; BALKAN PENINSULA; CHEMOPROPHYLAXIS; ETHNOLOGY; FEMALE; MALE; MASS SCREENING; MEDICATION COMPLIANCE; REFUGEE; STATISTICS; SWITZERLAND;

ADULT; AFRICA; ANTITUBERCULAR AGENTS; ASIA; BALKAN PENINSULA; CHEMOPREVENTION; COHORT STUDIES; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; ISONIAZID; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MEDICATION ADHERENCE; PROSPECTIVE STUDIES; REFUGEES; RIFAMPIN; SWITZERLAND;

EID: 84885097021     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2013.13860     Document Type: Article

References (27)

1. Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, White PJ, Abubakar I, Lalvani A. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis. 2011.
2. Horsburgh CR, Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004;350(20):2060-7.
3. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. Interferon-{gamma} release assays for the diagnosis of latent M. tuberculosis infection: A systematic review and meta-analysis. Eur Respir J. 2010.
4. Leung CC, Rieder HL, Lange C, Yew WW. Treatment of latent infection with m. tuberculosis: update 2010. Eur Respir J. 2010.
5. Horsburgh CR, Jr., Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med. 2011;364(15):1441-8.
6. Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009;179(11):1055-60.
7. Bennett DE, Courval JM, Onorato I, Agerton T, Gibson JD, Lambert L, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med. 2008;177(3):348-55. (Pubitemid 351198380)
8. Leung CC, Rieder HL, Lange C, Yew WW. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J. 2011;37(3):690-711.
9. Horsburgh CR Jr., Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010;137(2):401-9.
10. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008;12(11):1235-54.
11. Eidlitz-Markus T, Zeharia A, Baum G, Mimouni M, Amir J. Use of the urine color test to monitor compliance with isoniazid treatment of latent tuberculosis infection. Chest. 2003;123(3):736-9. (Pubitemid 36315486)
12. Sarivalasis A, Zellweger J, Faouzi M, Daher O, Deslarzes C, Bodenmann P. Factors associated with latent tuberculosis among asylum seekers in Switzerland: a cross-sectional study in Vaud County. BMC Infectious Diseases. 2012;12:285.
13. Ligue Pulmonaire S. Manuel de la tuberculose (2e edit). Ligue Pulmonaire Suisse, www.tbinfo.ch, Berne, 2007.
14. Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W. Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis. 2010;14(9):1104-11.
15. Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis. 2010;14(5):551-9.
16. Fresard I, Bridevaux PP, Rochat T, Janssens JP. Adverse effects and adherence to treatment of rifampicine 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis. Swiss Med Wkly. 2011;141: w13240.
17. Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med. 2006;174(6):717-21. (Pubitemid 44395341)
18. Marais BJ, van ZS, Schaaf HS, van AM, Gie RP, Beyers N. Adherence to isoniazid preventive chemotherapy: a prospective community based study. Arch Dis Child. 2006;91(9):762-5. (Pubitemid 44351177)
19. Breuss E, Helbling P, Altpeter E, Zellweger JP. Screening and treatment for latent tuberculosis infection among asylum seekers entering Switzerland. Swiss Med Wkly. 2002;132(15-16):197-200. (Pubitemid 34693351)
20. Racine-Perreaud E, Zellweger JP. Chimioth,rapie antituberculeuse preventive chez 250 patients du Dispensaire antituberculeux de Lausanne. Schweiz Med Wschrift. 1994;124:705-11. (Pubitemid 24146493)
21. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170(4):445-9. (Pubitemid 39214621)
22. Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149(10):689-97.
23. Langenskiold E, Herrmann FR, Luong BL, Rochat T, Janssens JP. Contact tracing for tuberculosis and treatment for latent infection in a low incidence country. Swiss Med Wkly. 2008;138(5-6):78-84. (Pubitemid 351252425)
24. Bodenmann P, Vaucher P, Wolff H, Favrat B, de Tribolet F, Masserey E, et al. Screening for latent tuberculosis infection among undocumented immigrants in Swiss healthcare centres; a descriptive exploratory study. BMC Infectious Diseases. 2009;9(1):34.
25. MacIntyre CR, Plant AJ, Yung A, Streeton JA. Missed opportunities for prevention of tuberculosis in Victoria, Australia. Int J Tuberc Lung Dis. 1997;1:135-41. (Pubitemid 127509669)
26. Mulder C, van Deutekom H, Huisman EM, Toumanian S, Koster BF, Meijer-Veldman W, et al. Role of the QuantiFERON(R)-TB Gold In-Tube assay in screening new immigrants for tuberculosis infection. Eur Respir J. 2012;40(6):1443-9.
27. Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis. 2008;12(12):1352-64.